Nektar Therapeutics (NASDAQ:NKTR) has a beta value of 0.79 and has seen 0.55 million shares traded in the recent trading session. The company, currently valued at $272.68M, closed the recent trade at $1.49 per share which meant it gained $0.17 on the day or 12.50% during that session. The NKTR stock price is -17.45% off its 52-week high price of $1.75 and 72.48% above the 52-week low of $0.41. The 3-month trading volume is 2.52 million shares.

Nektar Therapeutics (NASDAQ:NKTR) trade information

Sporting 12.50% in the green today, the stock has traded in the green over the last five days, when the NKTR stock price touched $1.49 or saw a rise of 0.67%. Year-to-date, Nektar Therapeutics shares have moved 162.83%, while the 5-day performance has seen it change 9.19%. Over the past 30 days, the shares of Nektar Therapeutics (NASDAQ:NKTR) have changed 58.96%.

Nektar Therapeutics (NKTR) estimates and forecasts

Figures show that Nektar Therapeutics shares have outperformed across the wider relevant industry. The company’s shares have gained 203.31% over the past 6 months, with this year growth rate of 32.41%, compared to 10.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 74.00% and 29.60% for the next quarter. Revenue growth from the last financial year stood is estimated to be -25.10%.

3 analysts offering their estimates for the company have set an average revenue estimate of $15.34 million for the current quarter. 3 have an estimated revenue figure of $15.34 million for the next quarter concluding in Jun 2024.

Earnings growth for 2024 is a modest 38.97% while over the next 5 years, the company’s earnings are expected to decrease by -7.30%.

NKTR Dividends

Nektar Therapeutics is expected to release its next earnings report in May this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.